terbinafine oral 250 mg
Selected indexed studies
- Efficacy and safety of 250 mg versus 500 mg oral terbinafine in the treatment of tinea corporis and cruris: A randomised, assessor-blinded comparative study. (Indian J Dermatol Venereol Leprol, 2023) [PMID:36688883]
- Oral terbinafine-induced bullous pemphigoid. (Ann Pharmacother, 2003) [PMID:14565807]
- Effectiveness and safety of oral terbinafine for dermatophyte distal subungual onychomycosis. (Expert Opin Pharmacother, 2024) [PMID:38221907]
_Worker-drafted node — pending editorial review._
Connections
terbinafine oral 250 mg is a side effect of
Sources
- Terbinafine: a review of its use in onychomycosis in adults. (2003) pubmed
- Pharmacokinetics of terbinafine in the nail. (1992) pubmed
- Effectiveness and safety of oral terbinafine for dermatophyte distal subungual onychomycosis. (2024) pubmed
- Onychomycosis in the elderly. (2000) pubmed
- Efficacy and safety of 250 mg versus 500 mg oral terbinafine in the treatment of tinea corporis and cruris: A randomised, assessor-blinded comparative study. (2023) pubmed
- Oral terbinafine-induced bullous pemphigoid. (2003) pubmed
- Comparison of one week of oral terbinafine (250 mg/day) with four weeks of treatment with clotrimazole 1% cream in interdigital tinea pedis. (1998) pubmed
- Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind, multicentre study. (1994) pubmed
- Oral Isotretinoin Combined with Oral Terbinafine Versus Oral Terbinafine Alone to Treat Recurrent Dermatophytosis: An Open-Label Randomised Clinical Trial. (2021) pubmed
- Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. (1998) pubmed